Organization
Hadassah Medical Moscow
2 abstracts
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).Org: Hadassah Medical Moscow, Srinagarind Hospital, Chris O’Brien Lifehouse,
Abstract
Nivolumab as second-line treatment of patients with metastatic renal cell carcinoma with high or normal fibrinogen levels: A prospective, cohort study.Org: Bureau for Cancer Research - BUCARE, City Clinical Cancer Hospital No. 1, Institute of Oncology Angel H Roffo, Hadassah Medical Moscow, State Budgetary Healthcare Institution Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care,